← Back to headlines
Alexion AstraZeneca Aims to Expand Rare Disease Therapies by 2030
Dr. Soraya Bekkali, Senior Vice President at Alexion, AstraZeneca Rare Disease, stated that a significant portion of the therapies the company plans to introduce by 2030 will focus on the area of rare diseases.
27 Jul, 20:08 — 27 Jul, 20:08